Influenza and COVID- 19: What does co- existence mean?
dc.contributor.author | Chotpitayasunondh, Tawee | |
dc.contributor.author | Fischer, Thea Kølsen | |
dc.contributor.author | Heraud, Jean‐michel | |
dc.contributor.author | Hurt, Aeron C. | |
dc.contributor.author | Monto, Arnold S. | |
dc.contributor.author | Osterhaus, Albert | |
dc.contributor.author | Shu, Yuelong | |
dc.contributor.author | Tam, John S. | |
dc.date.accessioned | 2021-05-12T17:26:00Z | |
dc.date.available | 2022-06-12 13:25:59 | en |
dc.date.available | 2021-05-12T17:26:00Z | |
dc.date.issued | 2021-05 | |
dc.identifier.citation | Chotpitayasunondh, Tawee; Fischer, Thea Kølsen ; Heraud, Jean‐michel ; Hurt, Aeron C.; Monto, Arnold S.; Osterhaus, Albert; Shu, Yuelong; Tam, John S. (2021). "Influenza and COVID- 19: What does co- existence mean?." Influenza and Other Respiratory Viruses (3): 407-412. | |
dc.identifier.issn | 1750-2640 | |
dc.identifier.issn | 1750-2659 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/167518 | |
dc.description.abstract | The COVID- 19 pandemic caused by the novel coronavirus SARS- CoV- 2 continues to have a major impact on healthcare and social systems throughout the world. As the clinical and epidemiological features of COVID- 19 have many parallels with influenza, it is important to ensure optimal management of both respiratory diseases as we anticipate their continued co- circulation. In particular, there is a need to ensure that effective surveillance and diagnostic capacities are in place to monitor these and other respiratory viruses, as this will underpin decisions on the appropriate clinical management of the respective diseases. As such, we propose a series of key recommendations for stakeholders, public health authorities, primary care physicians and surveillance bodies that will help mitigate the combined risks of concurrent influenza epidemics and the COVID- 19 pandemic. We advocate the judicious use of influenza vaccines and antivirals, particularly among groups at high risk of complications, with healthcare workers also considered a priority for vaccination. It is likely that the increased use of emerging technologies such as telemedicine and contact tracing will permanently change our approach to managing infectious disease. The use of these technologies, alongside existing pharmaceutical strategies, will ensure that we achieve a holistic approach to the global public health measures needed to deal with the combined threat of influenza and COVID- 19. Ensuring that this approach is optimal will be key as we move from a reactive pandemic response towards preparing for the long- term management of the remarkable clinical burden associated with these respiratory pathogens. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | surveillance | |
dc.subject.other | clinical management | |
dc.subject.other | COVID- 19 | |
dc.subject.other | influenza | |
dc.subject.other | antivirals | |
dc.subject.other | SARS- CoV- 2 | |
dc.title | Influenza and COVID- 19: What does co- existence mean? | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Microbiology and Immunology | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/167518/1/irv12824_am.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/167518/2/irv12824.pdf | |
dc.identifier.doi | 10.1111/irv.12824 | |
dc.identifier.source | Influenza and Other Respiratory Viruses | |
dc.identifier.citedreference | Sakamoto H, Ishikane M, Ueda P. Seasonal influenza activity during the SARS- CoV- 2 outbreak in Japan. JAMA. 2020; 323 ( 19 ): 1969 - 1971. | |
dc.identifier.citedreference | ECDC. Expert Opinion on Neuraminidase Inhibitors for the Prevention and Treatment of Influenza. 2017. https://www.ecdc.europa.eu/sites/default/files/documents/Scientific- advice- neuraminidase- inhibitors- 2017.pdf. Accessed August 2020. | |
dc.identifier.citedreference | WHO. WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and Other Influenza Viruses. 2010; https://www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf. Accessed August 2020. | |
dc.identifier.citedreference | WHO. Coronavirus Disease (COVID- 19) Advice for the Public. 2020; https://www.who.int/emergencies/diseases/novel- coronavirus- 2019/advice- for- public. Accessed August 2020. | |
dc.identifier.citedreference | WHO. Operational Considerations for COVID- 19 Surveillance Using GISRS. 2020; https://appswhoint/iris/bitstream/handle/10665/331589/WHO- 2019- nCoV- Leveraging_GISRS- 20201- engpdf. Last accessed June 2020. | |
dc.identifier.citedreference | Kandel N. Is there a business continuity plan for emergencies like an Ebola outbreak or other pandemics? J Bus Contin Emer Plan. 2015; 8 ( 4 ): 295 - 298. | |
dc.identifier.citedreference | The Academy of Medical Sciences. Preparing for a Challenging Winter 2020/21. 2020; https://acmedsci.ac.uk/file- download/51353957. Accessed August 2020. | |
dc.identifier.citedreference | Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of co- infection between SARS- CoV- 2 and other respiratory pathogens. JAMA. 2020; 323 ( 20 ): 2085 - 2086. | |
dc.identifier.citedreference | Khodamoradi Z, Moghadami M, Lotfi M. Co- infection of coronavirus disease 2019 and influenza A: a report from Iran. Arch Iran Med. 2020; 23 ( 4 ): 239 - 243. | |
dc.identifier.citedreference | Wang M, Wu Q, Xu W, et al. Clinical diagnosis of 8274 samples with 2019- novel coronavirus in Wuhan. 2020:2020.2002.2012.20022327. | |
dc.identifier.citedreference | Ding Q, Lu P, Fan Y, Xia Y, Liu M. The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China. J Med Virol. 2020; 92 ( 9 ): 1549 - 1555. | |
dc.identifier.citedreference | Wu X, Cai Y, Huang X, et al. Co- infection with SARS- CoV- 2 and influenza A virus in patient with pneumonia, China. Emerg Infect Dis. 2020; 26 ( 6 ): 1324 - 1326. | |
dc.identifier.citedreference | Casalegno JS, Ottmann M, Duchamp MB, et al. Rhinoviruses delayed the circulation of the pandemic influenza A (H1N1) 2009 virus in France. Clin Microbiol Infect. 2010; 16 ( 4 ): 326 - 329. | |
dc.identifier.citedreference | Nickbakhsh S, Mair C, Matthews L, et al. Virus- virus interactions impact the population dynamics of influenza and the common cold. Proc Natl Acad Sci USA. 2019; 116 ( 52 ): 27142 - 27150. | |
dc.identifier.citedreference | Cowling BJ, Ali ST, Ng TWY, et al. Impact assessment of non- pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study. Lancet Public Health. 2020; 5 ( 5 ): e279 - e288. | |
dc.identifier.citedreference | Wu D, Lu J, Liu Y, Zhang Z, Luo L. Positive effects of COVID- 19 control measures on influenza prevention. Int J Infect Dis. 2020; 95: 345 - 346. | |
dc.identifier.citedreference | WHO. Influenza Update. 2020; https://www.who.int/influenza/surveillance_monitoring/updates/latest_update_GIP_surveillance/en/. Accessed August 2020. | |
dc.identifier.citedreference | Soo RJJ, Chiew CJ, Ma S, Pung R, Lee V. Decreased influenza incidence under COVID- 19 control measures, Singapore. Emerg Infect Dis. 2020; 26 ( 8 ): e201229. | |
dc.identifier.citedreference | Troeger CE, Blacker BF, Khalil IA, et al. Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. Lancet Res Med. 2019; 7 ( 1 ): 69 - 89. | |
dc.identifier.citedreference | OECD. Influenza Vaccination Rates. 2020; https://data.oecd.org/healthcare/influenza- vaccination- rates.htm. Accessed August 2020. | |
dc.identifier.citedreference | Hughes MM, Reed C, Flannery B, et al. Projected population benefit of increased effectiveness and coverage of influenza vaccination on influenza burden in the United States. Clin Infect Dis. 2019; 70 ( 12 ): 2496 - 2502. | |
dc.identifier.citedreference | CDC. Past Seasons Vaccine Effectiveness Estimates. 2020; https://www.cdc.gov/flu/vaccines- work/past- seasons- estimates.html. Accessed August 2020. | |
dc.identifier.citedreference | Feng S, Chiu SS, Chan ELY, et al. Effectiveness of influenza vaccination on influenza- associated hospitalisations over time among children in Hong Kong: a test- negative case- control study. Lancet Res Med. 2018; 6 ( 12 ): 925 - 934. | |
dc.identifier.citedreference | Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir Marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018; 379 ( 10 ): 913 - 923. | |
dc.identifier.citedreference | Ison MG, Portsmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high- risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE- 2): a randomised, placebo- controlled, phase 3 trial. Lancet Infect Dis. 2020; 20 ( 10 ): 1204 - 1214. | |
dc.identifier.citedreference | Wang C- B, Chiu M- L, Lin P- C, et al. Prompt oseltamivir therapy reduces medical care and mortality for patients with influenza infection: an Asian Population Cohort Study. Medicine (Baltimore). 2015; 94 ( 27 ): e1070. | |
dc.identifier.citedreference | Sutton SS, Magagnoli J, Cummings T, Hardin J. Association between the use of antibiotics, antivirals, and hospitalizations among patients with laboratory confirmed influenza. Clin Infect Dis. 2020. Online ahead of print | |
dc.identifier.citedreference | Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta- analysis of individual participant data. Lancet Respir Med. 2014; 2 ( 5 ): 395 - 404. | |
dc.identifier.citedreference | Gutiérrez- Pizarraya A, Pérez- Romero P, Alvarez R, et al. Unexpected severity of cases of influenza B infection in patients that required hospitalization during the first postpandemic wave. J Infect. 2012; 65 ( 5 ): 423 - 430. | |
dc.identifier.citedreference | Biggerstaff M, Cauchemez S, Reed C, Gambhir M, Finelli L. Estimates of the reproduction number for seasonal, pandemic, and zoonotic influenza: a systematic review of the literature. BMC Infect Dis. 2014; 14: 480. | |
dc.identifier.citedreference | Liu Y, Gayle AA, Wilder- Smith A, Rocklov J. The reproductive number of COVID- 19 is higher compared to SARS coronavirus. J Travel Med. 2020; 27 ( 2 ): taaa021. | |
dc.identifier.citedreference | Petersen E, Koopmans M, Go U, et al. Comparing SARS- CoV- 2 with SARS- CoV and influenza pandemics. Lancet Infect Dis. 2020; 20 ( 9 ): e238 - e244. | |
dc.identifier.citedreference | WHO. Q&A: Influenza and COVID- 19 - Similarities and Differences. 2020; https://www.who.int/emergencies/diseases/novel- coronavirus- 2019/question- and- answers- hub/q- a- detail/q- a- similarities- and- differences- covid- 19- and- influenza. Accessed August 2020. | |
dc.identifier.citedreference | Ludvigsson JF. Systematic review of COVID- 19 in children shows milder cases and a better prognosis than adults. Acta Paediatr (Oslo, Norway: 1992). 2020; 109 ( 6 ): 1088 - 1095. | |
dc.identifier.citedreference | Viner RM, Whittaker E. Kawasaki- like disease: emerging complication during the COVID- 19 pandemic. Lancet. 2020; 395 ( 10239 ): 1741 - 1743. | |
dc.identifier.citedreference | Hennon TR, Penque MD, Abdul- Aziz R, et al. COVID- 19 associated Multisystem Inflammatory Syndrome in Children (MIS- C) guidelines; a Western New York approach. Prog Pediatr Cardiol. 57, 2020; 101232. | |
dc.identifier.citedreference | CDC. If You Are Immunocompromised, Protect Yourself From COVID- 19. 2020; https://www.cdc.gov/coronavirus/2019- ncov/need- extra- precautions/immunocompromised.html. Accessed August 2020. | |
dc.identifier.citedreference | Buekens P, Alger J, Breart G, Cafferata ML, Harville E, Tomasso G. A call for action for COVID- 19 surveillance and research during pregnancy. Lancet Glob Health. 2020; 8 ( 7 ): e877 - e878. | |
dc.identifier.citedreference | Kirby T. Evidence mounts on the disproportionate effect of COVID- 19 on ethnic minorities. Lancet Respir Med. 2020; 8 ( 6 ): 547 - 548. | |
dc.identifier.citedreference | Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin- angiotensin- aldosterone system inhibitors in patients with Covid- 19. N Engl J Med. 2020; 382 ( 17 ): 1653 - 1659. | |
dc.identifier.citedreference | Nickbakhsh S, Ho A, Marques DFP, McMenamin J, Gunson RN, Murcia PR. Epidemiology of seasonal coronaviruses: establishing the context for the emergence of Coronavirus Disease 2019. J Infect Dis. 2020; 222 ( 1 ): 17 - 25. | |
dc.identifier.citedreference | Zhou XD, Shu G, Ting F, et al. The Outbreak of Coronavirus Disease 2019 Interfered with Influenza in Wuhan. http://dxdoiorg/102139/ssrn3555239. 2020. | |
dc.identifier.citedreference | CDC. Influenza Antiviral Medications: Summary for Clinicians. 2020; https://www.cdc.gov/flu/professionals/antivirals/summary- clinicians.htm. Accessed August 2020. | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.